NUWE NUWELLIS INC

Nuwellis to Present at the Third Annual ROTH Healthcare Opportunities Conference

Nuwellis to Present at the Third Annual ROTH Healthcare Opportunities Conference

MINNEAPOLIS, Sept. 25, 2024 (GLOBE NEWSWIRE) -- (Nasdaq: NUWE), a medical technology company dedicated to transforming the lives of patients with fluid overload, is pleased to announce that President and Chief Executive Officer Nestor Jaramillo will participate in ROTH Capital Partners’ third annual on Wednesday, October 9, 2024.

Investor presentations and other materials used at the conference will be available on the investor relations section of . Parties interested in attending the conference and meeting with Nuwellis may contact their ROTH representative, submit a registration request online, or contact Vivian Cervantes, Gilmartin Group, at .

About Nuwellis

Nuwellis, Inc. (Nasdaq: NUWE) is a medical technology company dedicated to transforming the lives of patients suffering from fluid overload through science, collaboration, and innovation. The company is focused on commercializing the Aquadex SmartFlow® system for ultrafiltration therapy. Nuwellis is headquartered in Minneapolis, with a wholly owned subsidiary in Ireland. For more information visit or visit us on or .

About the Aquadex SmartFlow® System

The Aquadex SmartFlow system delivers clinically proven therapy using a simple, flexible and smart method of removing excess fluid from patients suffering from hypervolemia (fluid overload). The Aquadex SmartFlow system is indicated for temporary (up to 8 hours) or extended (longer than 8 hours in patients who require hospitalization) use in adult and pediatric patients weighing 20 kg or more whose fluid overload is unresponsive to medical management, including diuretics. All treatments must be administered by a health care provider, within an outpatient or inpatient clinical setting, under physician prescription, both having received training in extracorporeal therapies.

CONTACTS

Investors:

Vivian Cervantes

Gilmartin Group



EN
25/09/2024

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on NUWELLIS INC

 PRESS RELEASE

Nuwellis to Present at the Third Annual ROTH Healthcare Opportunities ...

Nuwellis to Present at the Third Annual ROTH Healthcare Opportunities Conference MINNEAPOLIS, Sept. 25, 2024 (GLOBE NEWSWIRE) -- (Nasdaq: NUWE), a medical technology company dedicated to transforming the lives of patients with fluid overload, is pleased to announce that President and Chief Executive Officer Nestor Jaramillo will participate in ROTH Capital Partners’ third annual on Wednesday, October 9, 2024. Investor presentations and other materials used at the conference will be available on the investor relations section of . Parties interested in attending the conference and meeti...

 PRESS RELEASE

New Study Published in Current Problems in Cardiology Highlights Stati...

New Study Published in Current Problems in Cardiology Highlights Statistically Significant Reduction in Heart Failure Readmissions at 60 days when using the Aquadex Ultrafiltration Therapy MINNEAPOLIS, Aug. 27, 2024 (GLOBE NEWSWIRE) -- (Nasdaq: NUWE), a medical technology company dedicated to transforming the lives of patients with fluid overload, is pleased to announce the publication of a new study in demonstrating the effectiveness of Aquadex® ultrafiltration therapy in reducing 60 day hospital readmission rates for patients with acutely decompensated heart failure (ADHF) who are oth...

 PRESS RELEASE

Nuwellis Announces Pricing of $916,000 Registered Direct Offering Pric...

Nuwellis Announces Pricing of $916,000 Registered Direct Offering Priced At-The-Market Under Nasdaq Rules MINNEAPOLIS, Aug. 23, 2024 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (Nasdaq: NUWE) (“Nuwellis” or the “Company”), a medical technology company focused on transforming the lives of people with fluid overload, today announced that it has entered into a definitive securities purchase agreement with certain institutional investors for the purchase and sale of 496,901 shares of the Company’s common stock at a price of $1.8450 per share of common stock in a registered direct offering priced at-th...

 PRESS RELEASE

Nuwellis, Inc. Announces Second Quarter 2024 Financial Results

Nuwellis, Inc. Announces Second Quarter 2024 Financial Results MINNEAPOLIS, Aug. 13, 2024 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (Nasdaq: NUWE), a medical technology company focused on transforming the lives of people with fluid overload, today reported financial results for the second quarter ended June 30, 2024. Highlights: Revenue of $2.2 million, a 6% increase over the second quarter of 2023.Critical Care revenue growth of 28% compared to the prior year quarter; Heart Failure consumables utilization growth of 35% over the prior-year quarter. Gross margin of 67.2%, compared to 55.3% in t...

 PRESS RELEASE

Nasdaq Panel Grants Nuwellis Continued Listing on the Nasdaq Stock Mar...

Nasdaq Panel Grants Nuwellis Continued Listing on the Nasdaq Stock Market, Subject to Conditions MINNEAPOLIS, Aug. 08, 2024 (GLOBE NEWSWIRE) -- (Nasdaq: NUWE), a medical technology company focused on transforming the lives of people with fluid overload (the “Company”), today announced The Nasdaq Hearings Panel (“Panel”) granted its request to continue its listing on the Nasdaq Stock Market, subject to certain conditions. The decision was based on information the Company presented to the Panel during a hearing on July 23, 2024. The letter received from the Panel stated that the continued...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch